DBV Technologies
{{Short description |French biopharmaceutical firm}}
{{Infobox company
| name = DBV Technologies SA
| logo = DBV Technologies logo.svg
| logo_size = 100px
| caption =
| trade_name = DBV Technologies
| romanized =
| former type =
| type = Société Anonyme
| traded_as = {{EuronextParis|DBV|FR0010417345|XPAR}}
{{Nasdaq|DBVT}}
CAC Small
| industry = Biotechnology
| genre =
| fate =
| predecessor =
| successor =
| foundation = Bagneux, France ({{Start date|2002}})
| founder = {{plainlist |
- Bertrand Dupont
- Christophe Dupont
}}
| location_city = Bagneux
| location_country = France
| locations =
| area_served =
| key_people = {{plainlist |
}}
| products = Allergy treatments, Allergy diagnosis
| production =
| services =
| revenue =
| operating_income =
| net_income =
| aum =
| assets =
| equity =
| owner =
| num_employees =
| parent =
| divisions =
| subsid =
| homepage = {{URL|www.dbv-technologies.com}}
| footnotes =
| intl =
| bodystyle =
}}
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration.{{cite web | url=https://www.bloomberg.com/quote/DBV:FP | title=DBV Technologies SA | publisher=Bloomberg | accessdate=February 8, 2013}}{{cite magazine|url=http://www.businessweek.com/news/2012-03-27/paris-is-europe-health-care-ipo-hub-with-most-sales-in-20-years |title=Paris Is Europe Health IPO Hub With Most Sales in 20 Years |magazine=Bloomberg Businessweek |date=March 28, 2012 |accessdate=February 8, 2013 |author=Albertina Torsoli |url-status=dead |archiveurl=https://web.archive.org/web/20120331023430/http://www.businessweek.com/news/2012-03-27/paris-is-europe-health-care-ipo-hub-with-most-sales-in-20-years |archivedate=March 31, 2012 }}{{cite web | url=http://www.dbv-technologies.com/about-us/presentation/ | title=Presentation | publisher=DBV Technologies | accessdate=February 8, 2013}}{{cite web | url=http://www.fiercebiotech.com/press-releases/dbv-technologies-and-centre-dimmunologie-de-marseille-luminy-ciml-enter-col | title=DBV Technologies and Centre d'Immunologie de Marseille-Luminy (CIML) enter in a Collaboration Agreement | date=17 October 2012 | publisher=FierceBiotech | accessdate=February 8, 2013}}{{cite web | url=http://clinicaltrials.gov/ct2/show/NCT01675882 | title=Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy (VIPES) | publisher=ClinicalTrials | accessdate=February 8, 2013}}{{cite web | url=http://www.bioworld.com/content/dbv-seeks-immunotherapeutic-desensitize-food-allergies?c2VhcmNoX3dvcmQ9YToyOntpOjA7czozOiJEQlYiO2k6MTtzOjEyOiJUZWNobm9sb2dpZXMiO30= | title=DBV Seeks Immunotherapeutic to Desensitize Food Allergies | publisher=BioWorld | date=January 16, 2013 | accessdate=February 8, 2013 | author=Marie Powers}}
History
DBV Technologies was founded in 2002 by Doctor Pierre-Henri Benhamou (specializing in Pediatric Gastroenterology), the engineer Bertrand Dupont (from the Arts et Métiers ParisTech in Paris) and Professor Christophe Dupont (head of the Neonatology Department Saint Vincent Hospital, Paris).{{cite web | url=http://www.ipdelivers.com/?q=content/pierre-henri-benhamou-dbv-technologies | title=Pierre-Henri Benhamou, DBV Technologies | publisher=Global Intellectual Property Center | accessdate=February 8, 2013}}{{cite web | url=http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=312261 | title=DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults | publisher=Evaluate Pharma | date=August 2, 2012 | accessdate=February 8, 2013}}{{cite web | url=http://www.beyondallergy.com/allergy-news/peanut-allergy-patch.php | title=Peanut Allergy Patch | publisher=Beyond Allergy | accessdate=February 8, 2013 | author=Heather Legg}}{{cite web | url=http://www.dbv-technologies.com/en/about-us/management/ | title=Management | publisher=DBV Technologies | accessdate=February 8, 2013 | archive-url=https://web.archive.org/web/20130317110130/http://www.dbv-technologies.com/en/about-us/management/ | archive-date=March 17, 2013 | url-status=dead }}
The founders provided initial startup capital. Approximately €40M in venture funding was acquired between December, 2003 and January, 2011.{{cite web | url=http://mtbeurope.info/news/2011/1102013.htm | title=DBV Technologies closes $25.5m financing round | publisher=MTB Europe | date=February 7, 2011 | accessdate=February 8, 2013}}{{cite web | url=http://www.news-medical.net/news/20110105/DBV-Technologies-secures-24255-million-in-Series-C-financing-round.aspx | title=DBV Technologies secures $25.5 million in Series C financing round | publisher=News Medical | date=January 5, 2011 | accessdate=February 8, 2013}} In March 2012, an initial public offering on the NYSE Euronext exchange yielded €40.5M (Euros).{{cite web | url=http://www.lundbeckfondventures.com/News.75/Successful-Initial-Public-Offering-(IPO)-for-DBV-Technologies-on-the-NYSE-Euronext-regulated-market-in-Paris.-DBV-Technologies-raises-%E2%82%AC-40.5-million.124.aspx | title=Successful Initial Public Offering (IPO) for DBV Technologies on the NYSE Euronext regulated market in Paris. DBV Technologies raises € 40.5 million. | publisher=Lundbeckfond Ventures | date=March 28, 2012 | accessdate=February 8, 2013 | archive-url=https://web.archive.org/web/20160304070924/http://www.lundbeckfondventures.com/News.75/Successful-Initial-Public-Offering-(IPO)-for-DBV-Technologies-on-the-NYSE-Euronext-regulated-market-in-Paris.-DBV-Technologies-raises-%E2%82%AC-40.5-million.124.aspx | archive-date=March 4, 2016 | url-status=dead }}{{cite web |url=https://www.nyse.com/press/1332932414974.html |title=NYSE Euronext welcomes DBV Technologies to its European market |publisher=NYSE Euronext |date=March 29, 2012 |accessdate=February 8, 2013 |url-status=dead |archiveurl=https://web.archive.org/web/20120607121151/http://www.nyse.com/press/1332932414974.html |archivedate=June 7, 2012 }}{{cite web|url=http://www.sofinnova.fr/sofinnova-partners-portfolio-company-dbv-news-1188.php |title=Sofinnova Partners' portfolio company DBV Technologies successfully raises €40.5M in its oversubscribed IPO |publisher=Sofinnova |date=March 29, 2012 |accessdate=February 8, 2013 }}{{dead link|date=December 2016 |bot=InternetArchiveBot |fix-attempted=yes }}
Daniel Tassé is CEO and Pascal Wotling is Chief Technical Operations Officer and Chief Quality Officer.
Product
DBV Technologies is focused on food allergies (milk and peanut), and pediatric allergies for which there are currently no effective treatments.{{cite web|url=http://www.bio.org/dbv-technologies-launches-its-third-viaskin%C2%AE-program-first-treatment-house-dust-mites-hdm-allergy-yo |archive-url=https://archive.today/20130414073827/http://www.bio.org/dbv-technologies-launches-its-third-viaskin%C2%AE-program-first-treatment-house-dust-mites-hdm-allergy-yo |url-status=dead |archive-date=April 14, 2013 |title=DBV Technologies launches its third Viaskin® program, a first for the treatment of House Dust Mites (HDM) allergy in young children |publisher=Biotechnology Industry Organization |date=November 14, 2012 |accessdate=February 8, 2013 }} It has developed two products: Viaskin Peanut for the treatment of peanut allergies and Viaskin Milk for cow's milk allergies.{{cite web|url=http://www.chicagochildrensresearch.org/uploadedFiles/Research/Clinical_Trials_Research/VIPES%20Brochure%20FINAL.pdf |title=Division of Allergy and Immunology |publisher=Chicago Children's Research |accessdate=February 8, 2013 }}
The Viaskin Peanut treatment helps patients tolerate exposure to peanut and thus lowers the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen.
The clinical development program for Viaskin Peanut has received "Fast Track" designation from the US Food and Drug Administration. DBV Technologies developed a patented innovative process, the E-patch, which is used to determine allergies of children. The ready-to-use standardised patch tests are highly reliable and conserve the allergic agents in their best state of allergy.{{cite news | url=https://www.telegraph.co.uk/health/healthnews/8544761/Skin-patch-could-cure-peanut-allergy.html | archive-url=https://web.archive.org/web/20110601231355/http://www.telegraph.co.uk/health/healthnews/8544761/Skin-patch-could-cure-peanut-allergy.html | url-status=dead | archive-date=June 1, 2011 | title=Skin patch could cure peanut allergy | newspaper=The Daily Telegraph | date=May 30, 2011 | accessdate=February 8, 2013}} In September 2014, DBV Technologies announced that its VIPES (Viaskin Peanut Efficacy and Safety) clinical trial of Viaskin Peanut achieved successful results in peanut allergy desensitization.{{cite web |url=http://globenewswire.com/news-release/2014/09/22/667595/10099521/en/DBV-Technologies-Announces-Primary-Endpoint-Met-in-VIPES-Viaskin-Peanut-s-Phase-IIb-Clinical-Trial-in-Peanut-Allergy.html#sthash.8aYGHFfo.dpuf |title=DBV Technologies Announces Primary Endpoint Met in VIPES, Viaskin Peanut's Phase IIb Clinical Trial in Peanut Allergy |date=22 September 2014 |accessdate=28 October 2014 |archive-url=https://web.archive.org/web/20141029080035/http://globenewswire.com/news-release/2014/09/22/667595/10099521/en/DBV-Technologies-Announces-Primary-Endpoint-Met-in-VIPES-Viaskin-Peanut-s-Phase-IIb-Clinical-Trial-in-Peanut-Allergy.html#sthash.8aYGHFfo.dpuf |archive-date=29 October 2014 |url-status=dead }}
References
{{reflist|2}}
External links
- [https://web.archive.org/web/20130703154556/http://www.dbv-technologies.com/en/ Official Website]
{{CAC Mid 60}}
Category:Companies based in Bagneux
Category:Medical technology companies of France
Category:Companies listed on Euronext Paris